- Ciscar, Marina
- Trinidad, Eva M.
- Pérez-Chacón, Gema
- Alsaleem, Mansour
- Jiménez, María
- Jiménez-Santos, María J.
- Pérez-Montoyo, Héctor
- Sanz-Moreno, Adrián
- Vethencourt, Andrea
- Toss, Michael
- Petit, Anna
- Soler-Monso, María T.
- López, Victor
- Gómez-Miragaya, Jorge
- Gómez-Aleza, Clara
- Dobrolecki, Lacey E.
- Lewis, Michael T.
- Bruna, Alejandra
- Mouron, Silvana
- Quintela-Fandino, Miguel
- Al-Shahrour, Fátima
- Martínez-Aranda, Antonio
- Sierra, Angels
- Green, Andrew R.
- Rakha, Emad
- González-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause., We thank Miguel Angel Pujana,Christian Tebe and Judith Pe~nafiel for the analyses of theIDBandCNIOcohorts, Sergi Velasco and Purificaci on Mu~noz for feedback about the manu-script. Work in the laboratory of EG-S has received funding from the SpanishMinisterio de Ciencia, Innovaci on y Universidades, which is part of AgenciaEstatal de Investigaci on (AEI) (SAF2014-55997-R, SAF2017-86117-R, andPID2020-116441GB-I00), the ISCIII (PIE13/00022) co-funded by EuropeanRegional Development Fund, a Career Catalyst Grant from the Susan KomenFoundation (CCR13262449), the Catalan Government2017SGR00665, co-funded by FEDER funds/European Regional Development Fund (ERDF) (a wayto build Europe), the European Research Council (ERC) under the EuropeanUnion’s Horizon2020research and innovation program (grant agreement no.682935), This study has been partially funded by Amgen Inc. EMT had receiveda Juan de la Cierva-Incorporaci on grant from Spanish Ministry of Science andInnovation (IJCI-2017-31564) and MG a PERIS contract from the Departamentof Salut de la Generalitat de Catalunya. The IDIBELL samples collection wasgranted by the Spanish Ministry of Health and Consumer Affairs FIS-PI14/00336from the I+D+I National Plan with the financial support from ISCIII-Subdirecci on General de Evaluaci on and the Fondo Europeo de DesarrolloRegional (FEDER). The generation of PDX models in the Lewis laboratory wassupported in part by NIH/NCI grants U54CA224076(MTL), U24CA226110(toMTL), P50CA186784(MTL) (Dan L. Duncan Cancer Center). This work was alsosupported by a Core Facility grant from the Cancer Prevention and ResearchInstitute of Texas (CPRIT Core Facilities Support Grant RP170691), Peer reviewed